Individualized Stabilization Criteria–Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion
To compare the 6-month efficacy and safety profile of an individualized stabilization criteria–driven pro re nata (PRN) regimen of ranibizumab 0.5 mg with or without laser versus laser alone in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO).
Powered by Versicherungsvergleich
Our Industry Partners
Empowering Excellence in Ophthalmology
We extend our deepest gratitude to our Platinum, Gold, and Silver partners. Your generous support fuels our mission to advance medical education, advocate for patient safety, and foster breakthrough innovations across West Virginia.
West Virginia Academy of Eye Physicians and Surgeons — advancing quality eye care through education, advocacy, and community awareness.
About
Resources
Advocacy